Melanie Cole (Host): Welcome to A HN Med Talks, an informative resource for
physicians across various specialties as we delve into the latest medical
insights and best practices, ensuring you stay at the forefront of your field.
I'm Melanie Cole, and today we're highlighting vulvar dysplasia
and when it could be cancerous.
Joining me is Dr.
Christopher Morse.
He's a gynecologic oncologist with the A HN Cancer Institute at West Penn Hospital.
Dr.
Morse, thank you so much for joining us today.
When we talk about vulvar dysplasia today, what spectrum.
Of disease, are we really referring to how has the terminology evolved
in recent years and why do we think it remains under-recognized, both by
patient's and at times by clinicians?
Dr Christopher Morse: Thank you so much for having me today, Melanie.
I think vulvar dysplasia is one of those, conditions that can often be, overlooked.
it is, not extremely common, but it does have some common.
symptoms that patient's might report to either their gynecologist or
perhaps their primary care physician.
But a lot of these symptoms might get, mis, diagnosed or misclassified
as perhaps, a urinary tract infection if the patient's complaining
of discomfort with urination.
but the most important thing is that.
primary care doctors or gynecologists listen to their patient's and, perform
an exam and if there's anything visually abnormal, do a biopsy.
Melanie Cole (Host): So then walk us through Dr.
Morse, the two main pathways of vulvar dysplasia.
There's HPV associated versus non HPV.
Why does that distinction matter clinically when
you're making this diagnosis?
Dr Christopher Morse: So there's a couple important, characteristics
or distinctions to make, when, thinking about vulvar dysplasia.
the majority of vulvar dysplasia is HPV mediated.
And we think of those, HPV media vulvar dysplasias into two categories, one being.
low grade vulvar dysplasia And the other being high grade, typically low grade
vulvar dysplasia, which is HPV mediated, is not thought to be pre-malignant.
meaning we don't think that over time it will become a vulvar cancer,
which ultimately is what we're trying to, prevent from happening.
High grade vulvar dysplasia, which is also HPV mediated, is something
that without treatment over time, can progress to become a vulvar cancer.
In contrast to, high and low grade vulvar dysplasia, That is HPV mediated.
We also have a entity called differentiated.
Vulvar dysplasia or differentiated VIN, and That is actually not typically
associated with HPV infection and is more commonly associated with underlying
vulvar dermatologic conditions such as lichen sclerosis most commonly.
Melanie Cole (Host): So when clinicians see their patient's,
which patient populations, Dr.
Morriss should immediately raise those red flags for progression risk.
And why?
Tell us a little bit about, patient's And what are they looking for?
Dr Christopher Morse: so one of the, first things that we can think about is.
In patient's who have HPV related vulvar dysplasia, they tend to be younger.
so typically, more in the mid forties, perhaps early fifties.
and classically, those, patient's are gonna present with either a
symptom, like a new lesion that they feel they might have itching.
Burning with urination are common symptoms, or they
might, report bleeding as well.
those patient's are also gonna have risk factors for HPV acquisition,
such as, cigarette smoking, immunosuppression perhaps, or they
might have a history of either prior vulvar dysplasia or cervical dysplasia.
And so Those are characteristics that we would see in that patient population.
In contrast to that.
Patient's who might have, differentiated VIN are typically
older, and This is not HPV associated.
And so these patient's might have a long history of untreated lichens sclerosis.
and those would be risk factors that, you would be asking for
in this patient population.
At the end of the day, the symptoms that they might present with or report,
might be the same, and ultimately a tissue diagnosis or a biopsy is gonna
be required, to kind of sort it all out.
Melanie Cole (Host): Okay, so, and This is really interesting and not something that.
Every clinician knows about what you're discussing here today.
So what histologic or clinical features would suggest that it may be progressing?
If you have diagnosed a patient that it may be progressing
towards an invasive cancer.
Are there specific symptoms that you'd like to mention to other providers?
Can't miss signals for malignancy.
Dr Christopher Morse: ultimately the biopsy will be what,
confirms the diagnosis of, either dysplasia or malignancy?
Certainly if a patient has a longstanding history.
of vulvar dysplasia that's gone either undiagnosed or untreated.
if the patient has a large lesion on clinical examination, That is firm, with
irregular borders or is bleeding, those would all be things that would make
me more concerned, that the, biopsy, might ultimately reveal a malignancy.
Melanie Cole (Host): along those lines then, Dr.
Morris, so how aggressive should clinicians be with biopsy?
Do you have some guidance that you could give for when watchful waiting
might no longer be appropriate?
Are there areas of the vulva that are more likely to harbor?
Malignancy and therefore warrant a lower threshold for biopsy.
Dr Christopher Morse: I would say at the end of the day, if a patient has a new
lesion or a persistent symptom that can't be explained, I would recommend that
clinicians have a very low threshold for performing a biopsy 'cause ultimately, the
biopsy will help guide for their therapy.
We'll either prove or demonstrate that the lesion is, benign, with no evidence
of dysplasia or malignancy, or it'll confirm the underlying suspicion that
This is a dysplastic or malignant lesion.
And then the patient can be referred for the appropriate, treatment, after
having a confirmed tissue diagnosis.
So if there's ever uncertainty, I always recommend, or if I'm seeing the
patient, I always would perform a biopsy.
Melanie Cole (Host): Well, thank you for, clearing that up about the threshold.
So how often do you see cancer present in patient's who might be previously thought
to have stable or lower grade disease?
Dr Christopher Morse: So certainly when you do a biopsy, sometimes
the pathologist, might, suggest that there is either a cancer
present or concern for, malignancy.
And then the other thing is that when you treat vulvar dysplasia, and oftentimes
This is treated with surgical excision.
There's always the risk of on your final pathology, detecting, an occult cancer
within the, final specimen, and that's probably in the range of five to 10%.
Melanie Cole (Host): Now let's talk about therapies available.
Tell us what's going on in your field.
As you know, you're always getting more tools in your toolbox, so speak a
little bit about the trade-offs between oncologic safety and preservation
of vulva anatomy and function.
And individualized treatments, topical therapy, surgical excision, surveillance.
Speak about all the treatment options available.
Dr Christopher Morse: Yeah.
So when we think about, how to treat vulvar dysplasia, you know, certainly
the, first and foremost goal is to prevent progression to malignancy.
So starting with low grade vulvar dysplasia, we don't
typically think that this.
Becomes malignant so often, as long as the patient's not, symptomatic,
we can recommend observation alone.
If we then think about, high grade vulvar dysplasia, high grade vulvar dysplasia
does have the potential of becoming malignant over time if untreated.
So essentially we think of three different treatment options, one.
Surgical excision.
The second would be ablative therapy with something called CO2 laser ablation.
And then the third would be topical therapy, with something called, imiquimod.
And when we think about, which patient we recommend, which
treatment for some important.
Factors or considerations that we might take in mind are the location of the
dysplasia, whether it's close to critical structures such as the clitoris, the
urethra, or the anus that might be impacted if you were to do surgery.
Whether there's just a single lesion or whether there's multiple lesions.
'cause the more.
Potential sites that you would have to resect could impact, the patient's
vulvar anatomy, whether the patient's an appropriate surgical candidate, And
then whether or not you're worried that there might be an underlying malignancy.
Certainly if there's ever a concern or a worry that there might be
an underlying malignancy, either because the pathology report or the
visual, your visual clinical exam.
Of the lesion then surgical excision is always favored
and recommended if feasible.
And finally, with differentiated VIN, there's a higher rate that
there might be either a malignancy or progression over time to malignancy.
So generally with differentiated VIN, we typically recommend in that situation
moving forward with surgical excision.
Melanie Cole (Host): So when we think of vulvar dysplasia, this
disease, any vulvar disease carries a unique emotional and sexual burden.
Dr.
Morse, how do you address this in clinical practice with your patient's?
So that shared decision-making is how you come up with your treatment modalities.
Dr Christopher Morse: Yeah, so important when you're discussing with the patient
potential options is, asking them and whether or not they're sexually active.
for some of our older patient's who are no longer, sexually active, some
of the considerations in terms of areas that you may or may not have
to resect, would become more or less, impactful in the decision-making.
But certainly making sure that you're having an informed.
Discussion with the patient to explore these things as it might
impact your decision for surgery or maybe avoiding surgery.
if certain structures like the clitoris might be impacted and
leaning towards a more ablative therapy, like CO2 laser ablation or
even a topical therapy like amicon.
Melanie Cole (Host): We are hearing more about the HPV vaccination.
It's been around a while now.
Dr.
Morris, how is that?
Impacting vulva dysplasia and cancer.
Are we fully leveraging its benefits?
Do you see a connection there?
Tell us about the vaccination itself.
Dr Christopher Morse: So currently in the United States, the, HPV vaccine is
targeted against nine different strains of HPV, many of the ones that do cause
underlying cervical and vulvar cancer.
So, over time, as the uptake of the HPV vaccination increases, we are seeing.
Decreasing rates of both vulvar and cervical dysplasia and malignancy.
So I think with time and with increased uptake, we are,
seeing the change over time.
Other things that we can also discuss with our patient's are, things like smoking
cessation, which is very important in patient's ability to clear HPV infection.
So all these things are things that we're.
discussing with the patient.
and oftentimes when we see the patient, initially we're focusing on the surgical
decision-making or the treatment options, But when we get them through their
course of, say, seeing them for their postoperative visit, we're making sure
that they've, received the HP vaccine or if they haven't and are still eligible
for it, making sure that they receive it.
And then also going over important things like, the importance of smoking cessation.
Melanie Cole (Host): Yeah.
These are all important points.
Dr.
Morris, as we wrap up, what's the single most important takeaway
that you'd like other clinicians to remember when deciding whether
vulva dysplasia could be cancerous?
If you could change one thing about how it's recognized or treated, what would
that be And what's that key takeaway?
Dr Christopher Morse: Yeah, I would say that the key takeaway is that, you
know, when patient's present with new symptoms or there's a lesion on exam
that doesn't have a clear diagnosis, when in doubt, perform a vulvar biopsy
to get a tissue diagnosis or refer, to your gynecologist or gwan oncologist
to help with treatment decision-making.
Then, any unexplained symptom, even in the absence of a visible lesion, would
warrant a biopsy so you can establish the tissue diagnosis and have the
patient get the appropriate treatment.
Melanie Cole (Host): You've given us really great straightforward
information for other clinicians.
Really a lot to think about.
Thank you so much, Dr.
Morse, for joining us today and to learn more or to refer your patient to Dr.
Morse, please call 8 4 4 md refer, or you can visit find care.ahn.org.
Thank you so much for listening to this edition of A HN Med Talks
with the Allegheny Health Network.
I'm Melanie Cole.